PVLA
Palvella Therapeutics Inc
NASDAQ · Biotechnology
$82.20
+5.77 (+7.55%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 450.02M | 396.70M | 170.23M | 158.95M | 134.45M |
| Net Income | -90,233,119 | -71,588,334 | 29.11M | 26.26M | 18.87M |
| EPS | — | — | — | — | — |
| Profit Margin | -57.3% | -54.5% | 17.1% | 16.5% | 14.0% |
| Rev Growth | +13.4% | +13.4% | -3.6% | +20.5% | +20.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 77.84M | 77.84M | 212.38M | 243.86M | 257.74M |
| Total Equity | 408.63M | 408.63M | 470.53M | 493.28M | 509.61M |
| D/E Ratio | 0.19 | 0.19 | 0.45 | 0.49 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -90,233,119 | -75,565,464 | 47.11M | 46.23M | 40.75M |
| Free Cash Flow | — | — | 10.70M | 10.92M | 9.19M |